Medical Intensive Care Unit
Welcome,         Profile    Billing    Logout  
 2 Trials 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Coupez, Elisabeth
LevoHeartShock, NCT04020263 / 2019-001563-74: Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock

Recruiting
3
610
Europe
Levosimendan 2.5 MG/ML Injectable Solution, Placebo
Central Hospital, Nancy, France
Cardiogenic Shock
02/27
01/28

Download Options